Auspherix Shortlisted for Biotech and Money’s ‘Start-Up UK Company of the Year’ Award

Auspherix, an early stage anti-infectives company, today announces that it has been shortlisted for the ‘Start-Up UK Company of the Year’ category of the inaugural Biotech and Money 2016 Awards.

Auspherix was nominated for the award and selected as a shortlisted finalist for its focus on developing new antibiotics in the fight against antimicrobial resistance and its commitment to UK bioscience. It also recognised the fact that the company has raised significant investment, given its pre-clinical stage of development: Auspherix announced a £6 million financing in 2015 by its seed investor Brandon Capital and new investor Imperial Innovations plc. Auspherix was co-founded by Dr Dagmar Alber and serial entrepreneur Professor Ian Charles and has attracted an impressive board, management team and scientific advisory board.

The winner of the award will be selected during final voting during the Biotech & Money Assembly and Gala Awards Dinner being held in London on 6 September 2016. Other finalists in the Start-Up UK Company of the Year Award category are Autolus, Blue Earth Diagnostics, Freeline Therapeutics, Mereo Biopharma, NightStarX, Orchard Therapeutics, Oxford Antibodies, Precision Ocular and Puridify.  Information on the awards can be found here.

Dr Neil Miller, CSO of Auspherix, said: “It is great that our pioneering work in the fight against antimicrobial resistance is being recognised. It is a credit to our founders that they identified innovative ways to identify new classes or antibiotics and to our investors who have recognised and backed the promise in our discoveries.”


Notes to Editors

About Auspherix Ltd

Auspherix Ltd has discovered a novel class of antibacterials with a profile suggestive of a novel mechanism of action and therefore offer the potential to address the rising global problem of resistance to current antibiotics. Its proprietary compound series show activity against a broad range of multidrug resistant (MDR) Gram-negative and Gram-positive bacteria, with profiles consistent with their use as antibacterial drugs for a number of indications with high unmet need and large market potential.

Based in Stevenage UK (in the Stevenage Bioscience Catalyst facility), the Company was founded in late 2013 based on discoveries made at the ithree institute at the University of Technology Sydney (UTS). The Company has raised AUS $2million in Seed investments (2013-2014) from Australia’s Medical Research Commercialisation Fund (MRCF) and £6 million in Series A round (2015) from the MRCF and the UK’s Imperial innovations plc (AIM IVO).

For further information please visit

For more information please contact:

Media Relations – Instinctif Partners

Sue Charles / Gemma Howe / Rosanna Forrest

T: +44 (0)20 7457 2020



Dr Neil Miller

T: +44 (0)1438 906755


0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply